Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LV232 multiple ascending doses and food effect study in healthy Chinese volunteers
NCT06279533Phase 1Completed
- Sponsor
- Vigonvita Life Sciences
- Start
- Feb 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LV232 (5 arms), sponsored by Vigonvita Life Sciences. Primary endpoints: Time to Maximum Plasma Concentration, Maximum Plasma Concentration and 4 more. Started Feb 2024; status: completed.
02
Drugs
LV232
Beyond the preview
Go deeper on NCT06279533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06279533.